[Effects of Ginkgolide B on inflammation induced by cerebral ischemia-reperfusion in rats].
OBJECTIVE
To investigate the protective effects of Ginkgolide B on inflammation induced by cerebral ischemia-reperfusion in rats.


METHODS
Rats were pretreated with Ginkgolide B at the dose of 2. 5, 5, 10 mg/kg for 3 days and then subjected to cerebral ischemia/reperfusion induced by a middle cerebral artery occlusion (MCAO). The infarct volume and the neurological deficit were determined by the method of TTC (2,3,5-triphenylterazolium chloride) staining and Longa's score. The permeability of blood-brain barrier (BBB) was evaluated by measurement of the evans blue (EB) content in the brain with spectrophotometer. The content of interleukin-1beta, interleukin-6 (IL-6, IL-1beta) in serum and tumor necrosis factor-alpha (TNF-alpha), The content of E-selectin and ICAM 1 in brain were determined by radio-immunoassay and ELISA assay.


RESULTS
Ginkgolide B reduced infarct volume, ameliorated the neurological deficit and the permeability of BBB, the content of IL-6, IL-1beta in serum and TNF-alpha, expressions of E-selectin and ICAM 1 in brain tissue also were significantly decreased.


CONCLUSIONS
Ginkgolide B has protective effects on cerebral injury by inhibiting the inflammation induced by ischemia/reperfusion injury.
Liu
Yong-Gang
YG
Department of pharmaceutical, Wujing Zongdui Hospital of Guangdong Province, Guangzhou 510507, China. liuyg1999@1631.com
Li
Fang-Jun
FJ
Wang
Jing
J
Wang
Xiao-Dong
XD
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications*; D004195:Disease Models, Animal; D019040:E-Selectin / Q000378:metabolism; D020441:Ginkgo biloba / Q000737:chemistry*; D046934:Ginkgolides / Q000008:administration & dosage / Q000494:pharmacology*; D020244:Infarction, Middle Cerebral Artery / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D018836:Inflammation Mediators / Q000097:blood* / Q000378:metabolism; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007783:Lactones / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology; D018515:Plant Leaves / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D019040:E-Selectin; D046934:Ginkgolides; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D007783:Lactones; D018696:Neuroprotective Agents; D014409:Tumor Necrosis Factor-alpha; C045856:ginkgolide B